Published in
Wiley, British Journal of Haematology, 6(178), p. 896-905, 2017
DOI: 10.1111/bjh.14787
Links
Tools
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
Journal article published in 2017 by
Meletios A. Dimopoulos 
,
Sagar Lonial,
Darrell White,
Philippe Moreau ,
Antonio Palumbo,
Jesus San-Miguel ,
Ofer Shpilberg,
Kenneth Anderson,
Sebastian Grosicki ,
Ivan Spicka,
Adam Walter-Croneck,
Hila Magen,
Maria-Victoria Mateos,
Andrew Belch,
Donna Reece
and other authors.
,
Sagar Lonial,
Darrell White,
Philippe Moreau ,
Antonio Palumbo,
Jesus San-Miguel ,
Ofer Shpilberg,
Kenneth Anderson,
Sebastian Grosicki ,
Ivan Spicka,
Adam Walter-Croneck,
Hila Magen,
Maria-Victoria Mateos,
Andrew Belch,
Donna Reece
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 